BioSpace News Archive

MicuRx Pharmaceuticals, Inc. announces that a poster on our preclinical product, MRX-6038, will be presented at ID Week entitled “In vitro Potency of a Leucyl-tRNA Synthetase Inhibitor, MRX-6038, Against Mycobacterium tuberculosis, Mycobacterium avium, and Mycobacterium abscessus.”

Valneva SE, a specialty vaccine company, announces it will present on the mosquito-borne chikungunya disease at several leading scientific conferences during the fourth quarter of 2023.

Neurolief, a global medical device company that is delivering life-changing neurotechnology innovations, today announced the appointment of Steve Beller, an experienced senior commercial leader in neurotechnology, as Chief Commercial Officer (CCO).

ARTHEx Biotech S.L. announced that it will participate in the 3rd Annual Needham Private Biotech Company Virtual 1x1 Forum, taking place October 17-18, 2023.

Oxford BioTherapeutics Ltd., a clinical stage oncology company with a pipeline of immuno-oncology and antibody-drug conjugate -based therapies, announced that it has relocated its UK headquarters to The Schrodinger Building within The Oxford Science Park.

Kintor Pharmaceutical Limited announced that its Hedgehog/SMO inhibitor GT1708F had obtained conditional approval to conduct Phase II clinical trial in China by the National Medical Products Administration for treatment of idiopathic pulmonary fibrosis.

Pathnostics, a leading diagnostic solutions company, announced the publication of clinical study results showing that its advanced urinary tract infection test profoundly impacts patient care.

Zomedica Corp., a veterinary health company offering diagnostic and therapeutic products for companion animals, announced that Larry Heaton, Chief Executive Officer, will present and host one-on-one meetings with investors at the Lytham Partners Fall 2023 Investor Conference, taking place virtually on October 17, 2023.

Sernova Corp. announced two oral presentations at the upcoming International Pancreas and Islet Transplant Association, International Xenotransplantation Association Cell Transplant & Regenerative Medicine Association joint congress taking October 26-29, 2023 in San Diego, CA.

Vyluma, Inc. announced positive top-line results from the second stage of its Phase III CHAMP clinical study of its lead compound, NVK002, a proprietary, investigational, preservative-free eye drop administered nightly and intended for patients ages 3 to 17.